DOCSLIB.ORG

Effects of Antidepressants on Weight and on the Plasma Levels of Leptin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Antidepressants on Weight and on the Plasma Levels of Leptin Effects of Antidepressants on Weight and on the Plasma Levels of Leptin, TNF-␣ and Soluble TNF Receptors: A Longitudinal Study in Patients Treated with Amitriptyline or Paroxetine Dunja Hinze-Selch, M.D., Andreas Schuld, M.D., Thomas Kraus, M.D., Martin Kühn, M.D., Manfred Uhr, M.D., Monika Haack, M.A., and Thomas Pollmächer, M.D. Leptin, tumor necrosis factor-␣ (TNF-␣), and soluble TNF preceded by a significant increase in soluble TNF receptor p75 receptors are involved in weight regulation. Antipsychotic plasma levels. Circulating levels of leptin were not affected. agents, such as clozapine, induce weight gain and increase Paroxetine and drug-free treatment did not affect any of these circulating levels of these cytokines. To assess whether obesity- parameters. We conclude that weight gain induced by inducing antidepressants have a similar effect, we measured psychotropic agents may occur without increased circulating plasma cytokine levels in depressive inpatients during the first levels of leptin. However, activation of the TNF-␣ system six weeks of treatment with tricyclic agents (amitriptyline or might be an early and sensitive marker of ensuing weight nortriptyline, n ϭ 12), with paroxetine (n ϭ 10), or without gain. [Neuropsychopharmacology 23:13–19, 2000] medication (n ϭ 14). There was an increase in the body mass © 2000 American College of Neuropsychopharmacology. index at week 6 of treatment with the tricyclics, which was Published by Elsevier Science Inc. All rights reserved KEY WORDS: Soluble TNF receptors; Leptin; Body mass al. 1996; Kraus et al. 1999). Although the effects of these index; Tricyclic antidepressants; Serotonin reuptake drugs on several neurotransmitter systems such as the inhibitor; Drug-free serotonergic, dopaminergic, and histaminergic systems Weight gain is a common side-effect of several psycho- may contribute to weight gain, the underlying mecha- tropic drugs and may seriously limit treatment compli- nisms have remained obscure (Pijl and Meinders 1996). ance (Pijl and Meinders 1996). Increases in weight occur Recently, however, research on obesity and weight in particular during treatment with tricyclic antidepres- regulation has contributed new perspectives through the sants (Berken et al. 1984) and the atypical neuroleptics discovery of leptin, a protein hormone involved in clozapine and olanzapine (Brömel et al. 1998; Bustillo et weight regulation (Pelleymounter et al. 1995; for review see Auwerx and Staels 1998), and tumor necrosis factor-␣ (TNF-␣), a cytokine with its soluble receptors as Janus- From the Max Planck Institute of Psychiatry, Munich, Germany. faced mediators of weight gain and weight loss (for re- Address correspondence to: Thomas Pollmächer, M.D., Max view see Argiles et al. 1997). Leptin induces reduced Planck Institute of Psychiatry, Kraepelinstrasse 10, D-80804 Munich, food intake, and dysregulated leptin signaling is ac- Germany. Received April 9, 1999; revised August 12, 1999; accepted January companied by obesity in animals and humans (for re- 3, 2000. view see Auwerx and Staels 1998). Animals that are de- NEUROPSYCHOPHARMACOLOGY 2000–VOL. 23, NO. 1 © 2000 American College of Neuropsychopharmacology Published by Elsevier Science Inc. All rights reserved 0893-133X/00/$–see front matter 655 Avenue of the Americas, New York, NY 10010 PII S0893-133X(00)00089-0 14 D. Hinze-Selch et al. NEUROPSYCHOPHARMACOLOGY 2000–VOL. 23, NO. 1 ficient in leptin or its receptor are obese and and has numerous hematological effects (for review see supplementation of this protein in leptin-deficient ani- van der Poll and Lowry 1995). In addition, we took the mals reverses obesity, supporting a pivotal role of lep- opportunity to investigate soluble interleukin-2 recep- tin in the regulation of appetite and weight (Lee et al. tor (sIL-2r) levels, which have been reported to be in- 1996, Pelleymounter et al. 1995). creased in patients with the diagnosis of major depres- In humans, plasma levels of leptin are higher in sion (Maes et al. 1995b) or schizophrenia (Gaughran et obese people than in lean controls and decrease with al. 1998). However, it has already been shown that psy- weight loss, suggesting a less sensitive receptor system chotropic medication, such as clozapine (Pollmächer et in obese people (Considine et al. 1996). In addition, the al. 1995, 1996), and cigarette smoking (Pollmächer and cytokine TNF-␣ and its soluble receptors sTNFR-p55 Hinze-Selch 1998) can also induce sIL-2r plasma levels. and sTNFR-p75 are associated with weight regulation. In a cross-sectional investigation on antidepressive TNF-␣ was described in 1981 as the molecule responsi- medication, no effect on circulating levels of sIL-2r was ble for the wasting syndrome in chronic diseases and found (Maes et al. 1995a), but a systematic longitudinal was named cachectin (Kawakami and Cerami 1981); study has not yet been published. later, it was sequenced and named tumor necrosis fac- We hypothesized that treatment with amitriptyline tor-␣ (Old 1985). TNF-␣ in concert with its receptors, or nortriptyline would induce weight gain and increase which are either bound to membranes of various cell plasma levels of leptin, TNF-␣, and soluble TNF recep- types or are shed into circulation, act on protein, glu- tors, whereas treatment with paroxetine and drug-free cose and lipid metabolism (for review see Argiles et al. treatment would not. 1997). Circulating levels of TNF-␣ and its soluble recep- tors are increased in obese subjects compared to lean controls and decrease with weight loss (Dandona et al. 1998; Hauner et al. 1998). It has been hypothesized that METHODS decreased TNF-␣ receptor sensitivity might lead to a Patients lack of body weight control and consequently to an in- crease in caloric intake (for review see Argiles et al. Twenty-two inpatients meeting the DSM-IV diagnostic 1997). In addition, in vitro and some in vivo data sug- criteria (American Psychiatric Association 1994) for ma- gest that the TNF-␣ system and leptin are linked to- jor depressive disorder or dysthymic disorder but not gether (Finck et al. 1998). Leptin with its class-I cytokine for bipolar disorder and 14 inpatients meeting the DSM- receptor modulates the cellular immune response, and IV diagnostic criteria for various other mental disorders, inflammatory cytokines such as TNF-␣ liberate leptin including anxiety disorders (n ϭ 5), adjustment disor- from adipocytes (for review see Argiles et al. 1997; Au- ders (n ϭ 3), schizophreniform disorder (n ϭ 1), and werx and Staels 1998). personality disorders (n ϭ 5), gave written informed Psychotropic drugs that typically lead to weight consent before participating in this study, which had gain, such as clozapine and olanzapine, have been been approved by an independent ethics committee. shown to activate the TNF-␣ system and leptin by in- None of the patients met the criteria for substance abuse creasing plasma levels of these cytokines and soluble or dependence, nor for any eating disorder. cytokine receptors (Brömel et al. 1998; Kraus et al. 1999; Physical examination, medical history and baseline Pollmächer et al. 1996). Therefore, the induction of laboratory investigations (white blood cell count, differ- these multifunctional mediators might play a role in ential counts, red blood cell count, creatinine, electro- drug-induced changes of body weight. lytes, GOT, GPT, AP, ␥GT, Quick, partial thromboplas- In the present study, designed to further evaluate tin time, serum electrophoresis, blood sedimentation this hypothesis, we investigated the time course of rate, C-reactive protein, serum iron, transferrin, glu- body weight and circulating levels of cytokines in de- cose, thyroid-stimulating hormone) did not reveal acute pressive inpatients during the first six weeks of treat- or chronic inflammation and infection or autoimmuno- ment with two antidepressant drugs with known dif- logical, endocrinological or hematological disease. Of ferent impacts on body weight. We also studied a the 22 patients with depressive or dysthymic disorder, group of unmedicated inpatients to control for unspe- 12 were medicated with amitriptyline (n ϭ 9) or cific effects of hospitalization per se. We chose the selec- nortriptyline (n ϭ 3) and 10 with paroxetine. The deci- tive serotonin reuptake inhibitor paroxetine that gener- sion about which substance to administer was based on ally does not affect body weight (Pijl and Meinders clinical considerations. 1996), and the tricyclic antidepressants amitriptyline or None of the patients had been treated during the its major active metabolite nortriptyline (Kessel and preceding six months with the substance he/she was to Simpson 1995) that induce weight gain (Berken et al. receive during the present study. Six of the 12 patients 1984). We also measured tympanic temperature and to be treated with amitriptyline/nortriptyline were not did white blood cell counts because TNF-␣ is pyrogenic psychopharmacologically treated during the preceding NEUROPSYCHOPHARMACOLOGY 2000–VOL. 23, NO. 1 Antidepressants, Weight, and Cytokines: A Longitudinal Study 15 six months. In the remaining six patients, psychotropic ml for leptin. The body mass index (BMI) was calcu- medication included fluspirilene, maprotilene, moclobe- lated as BMI ϭ body weight [kg] / height [m]2. mide, oxazepam, diazepam, and valproic acid and was discontinued before the enrollment in the study except Statistics for valproic acid, which was continued as mood stabi- lizer in one patient. Four of the 10 patients
Load more

Recommended publications
  • Mol.116.105981.Full.Pdf
    Molecular Pharmacology Fast Forward. Published on September 13, 2016 as DOI: 10.1124/mol.116.105981 This article has not been copyedited and formatted. The final version may differ from this version. MOL #105981 CURRENT KNOWLEDGE AND PERSPECTIVES FOR HISTAMINE H1 AND H2 RECEPTOR PHARMACOLOGY. FUNCTIONAL SELECTIVITY, RECEPTOR CROSSTALK AND REPOSITIONING OF CLASSIC HISTAMINERGIC LIGANDS. Downloaded from Federico Monczor and Natalia Fernandez. Instituto de Investigaciones Farmacológicas, ININFA. Universidad de Buenos Aires—Consejo molpharm.aspetjournals.org Nacional de Investigaciones Científicas y Técnicas, CONICET. Buenos Aires, Argentina. at ASPET Journals on September 28, 2021 1 Molecular Pharmacology Fast Forward. Published on September 13, 2016 as DOI: 10.1124/mol.116.105981 This article has not been copyedited and formatted. The final version may differ from this version. MOL #105981 Running title: Current and perspectives for histamine receptors pharmacology. Corresponding author: Federico Monczor. Laboratorio de Farmacología de Receptores. Instituto de Investigaciones Farmacológicas, ININFA. Universidad de Buenos Aires—Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET. Junin 956 (1113) Buenos Aires, Argentina. Tel:+54-11-5287-4856. e-mail: [email protected]. Total text pages: 41 Downloaded from Tables: 2 Figures: 1 References: 125 molpharm.aspetjournals.org Abstract words: 222 Abbreviations: AML, acute myeloid leukemia; ATP, adenosine triphosphate; GTP, guanosine triphosphate; AC, adenylyl cyclase; IP, inositol
    [Show full text]
  • THE USE of MIRTAZAPINE AS a HYPNOTIC O Uso Da Mirtazapina Como Hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa
    ARTIGO ESPECIAL THE USE OF MIRTAZAPINE AS A HYPNOTIC O uso da mirtazapina como hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa Prescription of approved hypnotics for insomnia decreased by more than 50%, whereas of antidepressive agents outstripped that of hypnotics. However, there is little data on their efficacy to treat insomnia, and many of these medications may be associated with known side effects. Antidepressants are associated with various effects on sleep patterns, depending on the intrinsic pharmacological properties of the active agent, such as degree of inhibition of serotonin or noradrenaline reuptake, effects on 5-HT1A and 5-HT2 receptors, action(s) at alpha-adrenoceptors, and/or histamine H1 sites. Mirtazapine is a noradrenergic and specific serotonergic antidepressive agent that acts by antagonizing alpha-2 adrenergic receptors and blocking 5-HT2 and 5-HT3 receptors. It has high affinity for histamine H1 receptors, low affinity for dopaminergic receptors, and lacks anticholinergic activity. In spite of these potential beneficial effects of mirtazapine on sleep, no placebo-controlled randomized clinical trials of ABSTRACT mirtazapine in primary insomniacs have been conducted. Mirtazapine was associated with improvements in sleep on normal sleepers and depressed patients. The most common side effects of mirtazapine, i.e. dry mouth, drowsiness, increased appetite and increased body weight, were mostly mild and transient. Considering its use in elderly people, this paper provides a revision about studies regarding mirtazapine for sleep disorders. KEYWORDS: sleep; antidepressive agents; sleep disorders; treatment� A prescrição de hipnóticos aprovados para insônia diminuiu em mais de 50%, enquanto de antidepressivos ultrapassou a dos primeiros.
    [Show full text]
  • Activation of 5-HT2C (But Not 5-HT1A) Receptors in the Amygdala Enhances Fear-Induced Antinociception: Blockade with Local 5-HT2C Antagonist Or Systemic fluoxetine
    Neuropharmacology 135 (2018) 376e385 Contents lists available at ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Activation of 5-HT2C (but not 5-HT1A) receptors in the amygdala enhances fear-induced antinociception: Blockade with local 5-HT2C antagonist or systemic fluoxetine Lígia Renata Rodrigues Tavares a, b, Daniela Baptista-de-Souza a, c, * Azair Canto-de-Souza a, b, c, d, a Psychobiology Group, Department of Psychology/CECH- Federal University of Sao~ Carlos-UFSCar, Sao~ Carlos, Sao~ Paulo, 13565-905, Brazil b Joint Graduate Program in Physiological Sciences UFSCar/UNESP, Sao~ Carlos, Sao~ Paulo, 13565-905, Brazil c Neuroscience and Behavioral Institute-IneC, Ribeirao~ Preto, Sao~ Paulo, 14040-901, Brazil d Program in Psychology UFSCar, Sao~ Carlos, Sao~ Paulo, 13565-905, Brazil article info abstract Article history: It is well-known that the exposure of rodents to threatening environments [e.g., the open arm of the Received 17 August 2017 elevated-plus maze (EPM)] elicits pain inhibition. Systemic and/or intracerebral [e.g., periaqueductal gray Received in revised form matter, amygdala) injections of antiaversive drugs [e.g., serotonin (5-HT) ligands, selective serotonin 5 March 2018 reuptake inhibitors (SSRIs)] have been used to change EPM-open arm confinement induced anti- Accepted 6 March 2018 nociception (OAA). Here, we investigated (i) the role of the 5-HT and 5-HT receptors located in the Available online 13 March 2018 1A 2C amygdaloid complex on OAA as well as (ii) the effects of systemic pretreatment with fluoxetine (an SSRI) on the effects of intra-amygdala injections of 8-OH-DPAT (a 5-HT1A agonist) or MK-212 (a 5-HT2C agonist) Keywords: fi Amygdala on nociception in mice con ned to the open arm or enclosed arm of the EPM.
    [Show full text]
  • FDA Approved Drugs with Broad Anti-Coronaviral Activity Inhibit SARS-Cov-2 in Vitro
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.25.008482; this version posted March 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro Stuart Weston1, Rob Haupt1, James Logue1, Krystal Matthews1 and Matthew B. Frieman*1 1 - Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore St., Room 380, Baltimore, MD, 21201, USA *Corresponding author. Email: [email protected] Key words: SARS-CoV-2, nCoV-2019, COVID-19, drug repurposing, FDA approved drugs, antiviral therapeutics, pandemic, chloroquine, hydroxychloroquine AbstraCt SARS-CoV-2 emerged in China at the end of 2019 and has rapidly become a pandemic with over 400,000 recorded COVID-19 cases and greater than 19,000 recorded deaths by March 24th, 2020 (www.WHO.org) (1). There are no FDA approved antivirals or vaccines for any coronavirus, including SARS-CoV-2 (2). Current treatments for COVID-19 are limited to supportive therapies and off-label use of FDA approved drugs (3). Rapid development and human testing of potential antivirals is greatly needed. A potentially quicker way to test compounds with antiviral activity is through drug re-purposing (2, 4). Numerous drugs are already approved for use in humans and subsequently there is a good understanding of their safety profiles and potential side effects, making them easier to test in COVID-19 patients.
    [Show full text]
  • Histamine Receptors
    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Paroxetine Shows No Effect on Drinking
    28 Addiction Psychiatry C LINICAL P SYCHIATRY N EWS • September 2007 Paroxetine Shows No E VIDENCE-BASED P SYCHIATRIC M EDICINE Effect on Drinking Abuse of Bupropion BY MICHELE G. SULLIVAN The patients’ average age was 29 The Problem caloric intake, or sleep. On self-rating scales, Mid-Atlantic Bureau years; 50% were male. At base- You work in one of America’s contemporary bupropion was perceived as an active drug only line, their mean score on the Lei- long-term psychiatric treatment centers, also as often as placebo. The investigators con- C HICAGO — Paroxetine can bowitz Social Anxiety Scale (LSAS) known as a state prison. Inmates who come to cluded, “It is unlikely that bupropion will give take the anxiety out of the drinker, was about 90, indicating severe so- outpatient appointments and complain of de- rise to [amphetaminelike] patterns of abuse but it cannot take the drinking out cial anxiety. Anxiety had its onset pressive symptoms frequently request bupro- among normals or among those predisposed of the anxious person. at age 12 years in these patients; pion (Wellbutrin). The history they provide is to psychostimulant abuse.” (The study came The drug did uncouple anxiety the use of alcohol to cope with speciously similar: “It’s the only antidepressant from the Baylor College of Medicine, the and drinking in patients who use symptoms followed about a that’s ever worked.” You start to inquire about Houston Veterans Administration Medical alcohol to cope with severe gener- decade later. They were moder- how this medication is used in the prison Center, and the Burroughs Wellcome Research alized social anxiety, Dr.
    [Show full text]
  • Monoamine Reuptake Inhibitors in Parkinson's Disease
    Hindawi Publishing Corporation Parkinson’s Disease Volume 2015, Article ID 609428, 71 pages http://dx.doi.org/10.1155/2015/609428 Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review article summarises all of the available literature on use of 50 MAUIs in PD. The compounds are divided according to their relative potency for each of the monoamine transporters.
    [Show full text]
  • Review Article Antidepressant Treatment for Acute Bipolar Depression: an Update
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Hindawi Publishing Corporation Depression Research and Treatment Volume 2012, Article ID 684725, 10 pages doi:10.1155/2012/684725 Review Article Antidepressant Treatment for Acute Bipolar Depression: An Update Ben H. Amit1, 2 and Abraham Weizman1, 2 1 Geha Mental Health Center, Research Unit, P.O. Box 102, Petach Tikva 49100, Israel 2 Sackler Faculty of Medicine, Tel Aviv University, P.O. Box 39040, Tel Aviv 69978, Israel Correspondence should be addressed to Ben H. Amit, [email protected] Received 23 October 2011; Accepted 29 November 2011 Academic Editor: Po-See Chen Copyright © 2012 B. H. Amit and A. Weizman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. While studies in the past have focused more on treatment of the manic phase of bipolar disorder (BD), recent findings demonstrate the depressive phase to be at least as debilitating. However, in contrast to unipolar depression, depression in bipolar patients exhibits a varying response to antidepressants, raising questions regarding their efficacy and tolerability. Methods.Weconducteda MEDLINE and Cochrane Collaboration Library search for papers published between 2005 and 2011 on the subject of antidepres- sant treatment of bipolar depression. Sixty-eight articles were included in the present review. Results. While a few studies did advo- cate the use of antidepressants, most well-controlled studies failed to show a robust effect of antidepressants in bipolar depression, regardless of antidepressant class or bipolar subtype.
    [Show full text]
  • Acute and Chronic Treatment with 5-HT Reuptake Inhibitors Differentially Modulate Emotional Responses in Anxiety Models in Rodents
    Psychopharmacology (1994) 113:463-470 Psychopharmacology © Springer-Verlag 1994 Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents Guy GriebeP, Jean-Luc Moreau 2, Francois Jenck 2, Ren6 Misslin 1, James R. Martin z 1 Laboratoire de Psychophysiologie, 7 rue de l'Universit~, F-67000 Strasbourg, France 2 Pharma Division, Prectinical Research, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland Received March 17, 1993 /FinaI version May 24, 1993 Abstract. This study investigated behavioural effects of 1992). However, several studies reported intriguing ob- very potent 5 HT reuptake inhibitors after acute treat- servations early in treatment (Saletu and Gfiinberger ment (cianopramine and citalopram), as well as after 1985; Gorman et al. 1987; Van Praag 1988 ;.Westenberg chronic treatment (cianopramine), in two behavioural and den Boer 1988; Humble et al. 1989; Giesecke 1990; models of anxiety: 1) the light/dark choice procedure in Montgomery 1991; Westenberg 1992). These authors mice and 2) the elevated plus-maze test in rats. In addi- noted activating effects at the beginning of treatment tion, the responses of mice to novelty in a free explora- with a 5-HT reuptake blocker, described as racing tion paradigm were assessed after acute administration thoughts, anxiety, nervousness, tremor, insomnia, jitteri- of both drugs. A single injection of cianopramine or ness, emotional discomfort and agitation; this effect dis- citalopram increased neophobic reactions in the free ex- appeared with subsequent treatment. It is hypothesized ploration test. Furthermore, these drugs increased the that the acute increased availability of 5-HT resulting avoidance reaction to a brightly illuminated chamber in from reuptake inhibition would initially produce an- the light/dark choice procedure as well as to open arms xiogenic-like effects until adaptive changes of the 5-HT in the elevated plus-maze test.
    [Show full text]
  • Geriatric Psychopharmacology: Anti-Depressants Amber Mackey, D.O
    Geriatric Psychopharmacology: Anti-depressants Amber Mackey, D.O. University of Reno School of Medicine Department of Psychiatry Chief Resident, PGY-4 Pharmacologic issues in the elderly More likely to experience drug induced adverse events Cardiac effects: Prolonged QTc, arrhythmias, sudden death Peripheral/central anticholinergic effects: constipation, delirium, urinary retention, delirium, and cognitive dysfunction Antihistaminergic effects: sedation Antiadrenergic effects: postural hypotension Other effects: Hyponatremia, bleeding, altered bone metabolism Pharmacokinetic Organ system Change consequence Circulatory system Decreased concentration Increased or decreased of plasma albumin and free concentration of drugs increased α1-acid in plasma glycoprotein Gastrointestinal Table tract 20-1 Decreased intestinal and Decreased rate of drug splanchnic blood flow absorption Kidney Decreased glomerular Decreased renal filtration rate clearance of active metabolites Liver Decreased liver size; Decreased hepatic decreased hepatic blood clearance flow; variable effects on cytochrome P450 isozyme activity Muscle Decreased lean body mass Altered volume of and increased adipose distribution of lipid-soluble tissue drugs, leading to increased elimination half-life Table 20-1, Physiological changes in elderly persons associated with altered pharmacokinetics, American Psychiatric Publishing Textbook of Geriatric Psychiatry, Fifth Edition, Chapter 20: Psychopharmacology. Other issues Illnesses that effect the elderly also play a role in diminishing
    [Show full text]
  • Current and Experimental Therapeutics of Insomnia
    133 CURRENT AND EXPERIMENTAL THERAPEUTICS OF INSOMNIA DANIEL J. BUYSSE CYNTHIA M. DORSEY 15% (4,5). Epidemiologic studies point to a consistent set of risk factors for insomnia. These include a previous history INSOMNIA: DEFINITIONS, IMPACT, AND of insomnia, increasing age, female gender, psychiatric DIAGNOSIS symptoms and disorders, medical symptoms and disorders, impaired activities of daily living, anxiolytic and hypnotic Definition of Insomnia Symptoms and medication use, and low socioeconomic status. The increas- Disorders ing prevalence of insomnia with age may be explained in large part by increasing comorbidity with medical and psy- Insomnia can refer to either a symptom or clinical disorder. chiatric disorders and medication use. The incidence of in- The symptom of insomnia is the subjective complaint of somnia also increases with age and is greater in women than difficulty falling or staying asleep, poor quality sleep, or men. On the other hand, remission of insomnia decreases inadequate sleep duration, despite having an adequate op- with age and is less common in women. Together, preva- portunity for sleep. Two points in this definition deserve lence, incidence, and remission data indicate that insomnia specific attention. First, insomnia is a subjective complaint is often a chronic condition. Between 50% and 80% of not currently defined by laboratory test results or a specific individuals with insomnia at baseline have a persistent com- duration of sleep or wakefulness. Second, the insomnia plaint after follow-up intervals of 1 to 3.5 years (1,6–8). symptom occurs despite the individual having adequate op- portunity to sleep. This distinguishes insomnia from sleep deprivation, which has different causes, consequences, and Impact of Insomnia clinical presentations.
    [Show full text]